Zacks.com on MSN11d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...
Armed robbery in Revesby6d
FDA Greenlights Pfizer's HYMPAVZI for Hemophilia A/B
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...
Pfizer Gets European Approval of Hympavzi Hemophilia Drug
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...
Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Pipeline, Epidemiology and Companies by DelveInsight
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
BioSpace9d
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
Nasdaq11d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...